Geoffrey R. Weiss
Primary AppointmentProfessor and Division Chief, Hematology and Oncology
- AB, Biology and Chemistry, Middlebury College, Middlebury, VT
- MD, Medicine, St. Louis University School of Medicine
- Internship, Internal Medicine, Temple University Hospital, Philadelphia, PA
- Residency, Internal Medicine, Temple University Hospital, Philadelphia, PA
- Chief Res, Internal Medicine, Temple University Hospital, Philadelphia, PA
- Clinical Fellowship, Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
New anticancer drug development, cancer immunotherapy
Geoffrey R. Weiss, M.D., Chief of the Division of Hematology-Oncology and Medical Director of the Cancer Center, is a medical oncologist and clinical investigator. During his previous appointment at the University of Texas Health Science Center at San Antonio, Dr. Weiss was an investigator of the Institute for Drug Development and contributed to the clinical advance of 40 new anticancer agents. Dr. Weiss has devoted much of his investigational career to the development of new therapies for genitourinary malignancies and for malignant melanoma. Since 1986, he has been a member of the Cytokine Working Group, a multi-institution clinical research consortium dedicated to the evaluation of cytokine-based therapies of renal cell carcinoma and malignant melanoma. This Group has been central to the development of high-dose interleukin-2 as an FDA-approved therapy of renal cell carcinoma and malignant melanoma.
Dr. Weiss joined the University of Virginia Cancer Center in November 2004. He is a member of the faculty of the Human Immune Therapy Center (HITC) and participates in the clinical trials of synthetic peptide vaccines for malignant melanoma. He has opened a clinical program utilizing high-dose interleukin-2 for the treatment of renal cell carcinoma and malignant melanoma, a resource soon to be applied to clinical trials of the Cytokine Working Group.